A. Jemal, F. Bray, M. Center, J. Ferlay, E. Ward et al., Global cancer statistics, CA: A Cancer Journal for Clinicians, vol.82, issue.19 suppl, pp.6169-90, 2011.
DOI : 10.3322/caac.20107

K. Field and L. Lipton, Metastatic colorectal cancer-past, progress and future, World Journal of Gastroenterology, vol.13, issue.28, pp.3806-3815, 2007.
DOI : 10.3748/wjg.v13.i28.3806

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4611212

D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg et al., Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer, New England Journal of Medicine, vol.351, issue.4, pp.337-345, 2004.
DOI : 10.1056/NEJMoa033025

D. Jonker, O. Callaghan, C. Karapetis, C. Zalcberg, J. Tu et al., Cetuximab for the Treatment of Colorectal Cancer, New England Journal of Medicine, vol.357, issue.20, pp.3572040-2048, 2007.
DOI : 10.1056/NEJMoa071834

E. Van-cutsem, M. Peeters, S. Siena, Y. Humblet, A. Hendlisz et al., Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.25, issue.13, pp.251658-1664, 2007.
DOI : 10.1200/JCO.2006.08.1620

E. Van-cutsem, C. Kohne, E. Hitre, J. Zaluski, C. Chien et al., Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.360, issue.14, pp.3601408-1417, 2009.
DOI : 10.1056/NEJMoa0805019

C. Bokemeyer, I. Bondarenko, A. Makhson, J. Hartmann, J. Aparicio et al., Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.27, issue.5, pp.663-671, 2009.
DOI : 10.1200/JCO.2008.20.8397

J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes et al., Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study, Journal of Clinical Oncology, vol.28, issue.31, pp.284697-4705, 2010.
DOI : 10.1200/JCO.2009.27.4860

D. Fiore, F. Sesboue, R. Michel, P. Sabourin, J. Frebourg et al., Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer, British Journal of Cancer, vol.25, issue.12, pp.1765-1772, 2010.
DOI : 10.1038/sj.bjc.6606008

S. Misale, R. Yaeger, S. Hobor, E. Scala, M. Janakiraman et al., Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature, vol.102, issue.7404, pp.486532-536
DOI : 10.1038/nature11156

A. Bardelli and S. Siena, Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer, Journal of Clinical Oncology, vol.28, issue.7, pp.1254-1261, 2010.
DOI : 10.1200/JCO.2009.24.6116

J. Paez, P. Janne, J. Lee, S. Tracy, H. Greulich et al., Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, issue.5676, pp.3041497-1500, 2004.

T. Lynch, D. Bell, R. Sordella, S. Gurubhagavatula, R. Okimoto et al., Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non???Small-Cell Lung Cancer to Gefitinib, New England Journal of Medicine, vol.350, issue.21, pp.3502129-2139, 2004.
DOI : 10.1056/NEJMoa040938

M. Moroni, S. Veronese, S. Benvenuti, G. Marrapese, A. Sartore-bianchi et al., Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study, The Lancet Oncology, vol.6, issue.5, pp.279-286, 2005.
DOI : 10.1016/S1470-2045(05)70102-9

P. Laurent-puig, A. Cayre, G. Manceau, E. Buc, J. Bachet et al., Metastatic Colon Cancer, Journal of Clinical Oncology, vol.27, issue.35, pp.275924-5930, 2009.
DOI : 10.1200/JCO.2008.21.6796

URL : https://hal.archives-ouvertes.fr/hal-00618089

M. Scartozzi, I. Bearzi, A. Mandolesi, C. Pierantoni, F. Loupakis et al., Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis, BMC Cancer, vol.26, issue.1, p.303, 2009.
DOI : 10.1200/JCO.2007.11.5022

J. Tol, J. Dijkstra, M. Klomp, S. Teerenstra, M. Dommerholt et al., Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab, European Journal of Cancer, vol.46, issue.11, pp.461997-2009, 2010.
DOI : 10.1016/j.ejca.2010.03.036

S. Khambata-ford, C. Garrett, N. Meropol, M. Basik, C. Harbison et al., Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab, Journal of Clinical Oncology, vol.25, issue.22, pp.253230-3237, 2007.
DOI : 10.1200/JCO.2006.10.5437

J. Baker, D. Dutta, D. Watson, T. Maddala, B. Munneke et al., Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer, British Journal of Cancer, vol.9, issue.3, pp.488-495, 2011.
DOI : 10.1126/science.1073096

Z. Yuan, J. Shin, A. Wilson, S. Goel, Y. Ling et al., An A13 Repeat within the 3'-Untranslated Region of Epidermal Growth Factor Receptor (EGFR) Is Frequently Mutated in Microsatellite Instability Colon Cancers and Is Associated with Increased EGFR Expression, Cancer Research, vol.69, issue.19, pp.697811-7818, 2009.
DOI : 10.1158/0008-5472.CAN-09-0986

R. Xicola, X. Llor, E. Pons, A. Castells, C. Alenda et al., Performance of Different Microsatellite Marker Panels for Detection of Mismatch Repair-Deficient Colorectal Tumors, JNCI Journal of the National Cancer Institute, vol.99, issue.3
DOI : 10.1093/jnci/djk033

K. Livak and T. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(?Delta Delta C(T)) Method, pp.402-408, 2001.

M. Vezain, P. Saugier-veber, J. Melki, A. Toutain, E. Bieth et al., A sensitive assay for measuring SMN mRNA levels in peripheral blood and in muscle samples of patients affected with spinal muscular atrophy, European Journal of Human Genetics, vol.64, issue.10, pp.151054-1062, 2007.
DOI : 10.1016/S0022-510X(99)00325-1

I. Hofacker, Vienna RNA secondary structure server, Nucleic Acids Research, vol.31, issue.13, pp.313429-3431, 2003.
DOI : 10.1093/nar/gkg599

URL : http://doi.org/10.1093/nar/gkg599

J. Reeder and R. Giegerich, Design, implementation and evaluation of a practical pseudoknot folding algorithm based on thermodynamics, BMC Bioinformatics, vol.5, issue.1, p.104, 2004.
DOI : 10.1186/1471-2105-5-104

C. Do, D. Woods, and S. Batzoglou, CONTRAfold: RNA secondary structure prediction without physics-based models, Bioinformatics, vol.22, issue.14, pp.90-98, 2006.
DOI : 10.1093/bioinformatics/btl246

URL : http://ai.stanford.edu/~serafim/Publications/2006_CONTRAfold.pdf

E. Bindewald, T. Kluth, and B. Shapiro, CyloFold: secondary structure prediction including pseudoknots, Nucleic Acids Research, vol.38, issue.Web Server, pp.368-372
DOI : 10.1093/nar/gkq432

URL : http://doi.org/10.1093/nar/gkq432

S. Baranovskaya, Y. Martin, S. Alonso, K. Pisarchuk, M. Falchetti et al., Down-regulation of Epidermal Growth Factor Receptor by Selective Expansion of a 5'-End Regulatory Dinucleotide Repeat in Colon Cancer with Microsatellite Instability, Clinical Cancer Research, vol.15, issue.14, pp.154531-4537, 2009.
DOI : 10.1158/1078-0432.CCR-08-1282

M. Deqin, Z. Chen, C. Nero, K. Patel, E. Daoud et al., Somatic Deletions of the PolyA Tract in the 3??? Untranslated Region of Epidermal Growth Factor Receptor Are Common in Microsatellite Instability???High Endometrial and Colorectal Carcinomas, Archives of Pathology & Laboratory Medicine, vol.136, issue.5, pp.510-516
DOI : 10.5858/arpa.2010-0638-OA

L. Morandi, D. De-biase, M. Visani, A. Monzoni, A. Tosi et al., Pession A: T([20]) repeat in the 3?-untranslated region of the MT1X gene: a marker with high sensitivity and specificity to detect microsatellite instability in colorectal cancer, Int J Colorectal Dis, vol.2012, issue.275, pp.647-656